乳腺癌组织中BRCA1的蛋白表达对乳腺癌新辅助化疗疗效的影响  

Effect of the expression of BRCA1 protein on the effect of the neoadjuvant chemotherapy for breast cancer

作　　者：赵善鹏[1] 于泽平[1] 顾军[1] 王海[2] 周航波[2] 

机构地区：[1]南京大学医学院临床学院(南京军区南京总医院)普通外科,南京医学硕士210002 [2]南京大学医学院临床学院(南京军区南京总医院)病理科,南京210002

出　　处：《医学研究生学报》2010年第10期1066-1069,共4页Journal of Medical Postgraduates

基　　金：南京军区南京总医院科研基金(2005045)

摘　　要：目的新辅助化疗是重要的乳腺癌综合治疗手段之一。BRCA1的过表达可以使损伤的DNA迅速修复,从而导致瘤细胞对化疗药物的耐药。文中探讨BRCA1蛋白的表达对乳腺癌新辅助化疗敏感性的影响。方法Envision法检测接受了新辅助化疗(TEC或CEF方案)的40例患者的BRCA1的蛋白表达,对比新辅助化疗前后B超检查结果以及术前术后病理诊断结果来综合评价化疗的有效性,分析这新辅助化疗有效组与无效组中BRCA1蛋白表达差异是否存在统计学意义。结果在20例新辅助化疗无效组中,16例的BRCA1蛋白呈高表达,20例新辅助化疗有效组中9例呈高表达。BRCA1蛋白在新辅助化疗无效组中的高表达率明显高于有效组,两者比较具有显著性差异(P<0.05)。结论BRCA1的蛋白表达程度可以作为乳腺癌新辅助化疗敏感性的预测指标之一。Objective Neoadjuvant chemotherapy is an important means of combined treatment of breast cancer.The overexpression of BRCA1 can promote the repair of DNA damage,leading to tumor cell resistance to chemotherapeutic drugs.This study was to investigate the relation of the expression of BRCA1 protein with the results of new adjuvant chemotherapy of breast cancer.Methods The expression of the BRCA1 protein was detected by Envision immunohistochemistry in 40 cases of breast cancer that underwent neoadjuvant chemotherapy（TEC or CEF）.The effects of the neoadjuvant chemotherapy were evaluated by B-ultrasound and pathological examination,and the differences in the BRCA1 protein expression were analyzed between the effective and ineffective groups.Results The BRCA1 protein was highly expressed in 9 of the 20 patients that responded to the neoadjuvant chemotherapy and in 16 of the 20 that failed to,significantly higher in the ineffective than in the effective group（P0.05）.Conclusion The expression of the BRCA1 protein might be a potential predictive marker of tumor response to neoadjuvant chemotherapy of breast cancer.

关 键 词：BRCA1 蛋白表达 免疫组织化学 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]